Skip to main content

What is Idhifa used to treat?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on May 9, 2024.

Official answer

by Drugs.com

Key Points

  • Idhifa (enasidenib) is an oral medication used to treat adult patients with acute myeloid leukemia (AML), a type of cancer of the blood and bone marrow. It is used if you have a specific genetic mutation known as IDH2 (isocitrate dehydrogenase-2).
  • Idhifa is used in patients with AML that has returned after initial treatment (relapsed) or has not responded to treatment (refractory).
  • It is not known if Idhifa is safe or effective in children.

Idhifa is approved to be used with the RealTime IDH2 Assay, a diagnostic that detects specific mutations in the IDH2 gene in patients with AML. IDH2 gene mutations may lead to immature blood cells becoming cancerous and dividing uncontrollably, causing AML.

How do I take Idhifa?

Take Idhifa exactly as your doctor orders. The recommended dose of Idhifa is 100 mg orally once daily. You can take your medicine with or without food. Take your dose at about the same time each day. Do not split or crush your tablets.

If you vomit after taking your medicine, you miss a dose, or you miss the usual time you take your medicine, take the dose as soon as possible on the same day, and return to the normal schedule the following day.

You will take Idhifa until your disease worsens or you have unacceptable side effects to the treatment. Your dose may need to be modified or treatment interrupted if you have certain side effects. In general, treatment will be continued for at least 6 months if possible.

Idhifa comes as 50 mg tablet and 100 mg oral tablet and is manufactured by Celgene.

This is not all the information you need to know about Idhifa (enasidenib) for safe and effective use. Review the full Idhifa information here, and discuss this information with your doctor or other health care provider.

Related Questions

References

Read next

Venclexta (venetoclax) is a targeted treatment rather than a type of chemotherapy. Chemotherapy is defined as a drug treatment that kills fast-growing cells in your body. Venclexta works by binding to a specific protein called BCL-2 which is overexpressed on cancerous cells in people with cancers such as AML and CLL. By binding to this protein Venclexta kills cancerous CLL and AML lymphocytes, in preference to other fast-growing cells. Continue reading

Venclexta (venetoclax) is effective for both CLL and AML with trials reporting significantly more people experiencing complete remission with Venclexta in combination with other treatments compared to standard therapy. Venclexta works quickly as well, with it taking an average of one month for many people to experience a reduction in disease progression. Continue reading

Venclexta is usually taken for 12 months by previously untreated patients with CLL or SLL and for 24 months for previously treated patients with CLL or SLL. For patients with AML, Venclexta is taken for as long as it is deemed safe to do so (until disease progression or unacceptable toxicity is observed). Continue reading

Related medical questions

Drug information

Related support groups

Medical Disclaimer